Abstract
The MDM2 protein is known to be overexpressed in some sarcomas including rhabdomyosarcoma. However, the extent to which the MDM2 protein influences sensitivity to chemotherapeutic drugs is unclear. We have analysed this further using stable transfection of the mdm2 gene into 4 well-characterised human paediatric rhabdomyosarcoma cell lines. Transfection with the mdm2 gene resulted in increased levels of the MDM2 protein in all the cell lines. In 2 of the lines, SCMC and RD, the mdm2 gene caused between 2-fold and 61-fold increase in resistance to vincristine, etoposide and doxorubicin but not to cisplatin. In these lines there was an increase in expression of the mdr-1 gene which encodes P-glycoprotein, but not the mrp1 gene which encodes the multidrug resistance protein (MRP). The resistance was reversible using the MDR modulator PSC833, confirming the presence of P-glycoprotein. We conclude that MDM2 overexpression may be a mechanism by which multidrug resistance is regulated in some rhabdomyosarcomas. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ashcroft M and Vousden KH (1999) Regulation of p53 stability. Oncogene 18: 7637–7643
Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH and Twentyman P (1994) A 190-kDa protein overexpressed in non-P-glycoprotein containing multidrug resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 86: 110–117
Bordow SB, Habrer M, Madafiglio J, Cheung B, Marshall GM and Norris MD (1994) Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Research 54: 5036–5040
Chan HSL, Thorner PS, Haddad G and Ling V (1990) Immunohistochemical detection of P-glycoprotein – Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689–704
Chin K-V, Ueda K, Pastan I and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459–462
Cocker HA, Pinkerton CR and Kelland LR (2000) Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. British Journal of Cancer 83: 338–345
Enzinger FM and Weiss SW (1995) Soft tissue tumors. The CV Mosby Co: St Louis
Hobbs S, Jitapakdee S and Wallace JC (1998) Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1α-promotor for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochemical and Biophysical Research Communications 252: 368–372
Keleti J, Quezado MM, Abaza MM, Raffeld M and Tsokos M (1996) The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. American Journal Pathology 149: 143–151
Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson JW, Morimura T, Takeuchi J and Barnett GH (1996) mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. British Journal of Cancer 74: 1263–1268
Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT and Houghton PJ (1996) P-Glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. Journal Clinical Oncology 14: 886–900
Leveillard T and Wasylyk B (1997) The MDM2 C-terminal region binds to TAF(II)250 and is required for MDM2 regulation of the cyclin A promoter. J Biological Chemistry 272: 30651–30661
Li ZH, Zhu YJ and Lit XT (1997) Wild-type p53 gene increases MDR1 gene expression but decreases drug resistance in an MDR cell line KBV200. Cancer Letters 119: 177–184
Meddeb M, Valent A, Danglot G, Nguyen VC, Duverger A, Fouquet F, Terrier-Lacombe MJ, Oberlin O and Bernheim A (1996) MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenetics Cell Genetics 73: 325–330
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal Immunological Methods 65: 55–63
Naito M and Tsuruo T (1997) New multidrug resistance reversing drugs, MS-209 and SDZ PSC833. Cancer Chemother Pharmacol 40: S20–S24
Peng Y, Chen L, Li C, Lu W, Agrawal S and Chen J (2001) Stabilization of the MDM2 oncoprotein by mutant p53. Journal Biological Chemistry 276: 6874–6878
Sharp SY, Rowlands MG, Jarman M and Kelland LR (1994) Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and resistant human ovarian carcinoma cell lines. British Journal of Cancer 70: 409–414
Suzuki A, Toi M, Yamamoto Y, Saji S, Muta M and Tominaga T (1998) Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Japan Journal Cancer Research 89: 221–227
Tanner B, Hengstler JG, Laubscher S, Meinert R, Oesch F, Weikel W, Knapstein PG and Becker R (1997) Mdm2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 74: 438–442
Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ and Harris LC (2000) p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Medicine Pediatric Oncology 35: 96–103
Thottassery JV, Zambetti GP, Arimori K, Schuetz EG and Schuetz JD (1997) p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci 94: 11037–11042
Zhou M, Gu L, Jurickova I, Yarrington AK, Absbire T, Homans A, Yeager AM and Findley HW (1997) Elevated MDM2 protein expression in pediatric acute lymphoblastic leukemia (ALL) is associated with in vitro resistance to adriamycin and decreased duration of first remission (CR1). Blood 90: 824–824
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Cocker, H., Hobbs, S., Tiffin, N. et al. High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 85, 1746–1752 (2001). https://doi.org/10.1054/bjoc.2001.2145
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.2145
Keywords
This article is cited by
-
The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells
Cell Death Discovery (2019)
-
Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53
Oncogene (2016)
-
Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma
Pediatric Surgery International (2007)
-
A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin
British Journal of Cancer (2004)
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Oncogene (2003)
